Get the Stockscreener App
1.951
8.26%
0.151
Climb Bio Inc stock is traded at $1.951, with a volume of 294.44K.
It is up +8.26% in the last 24 hours and down -13.39% over the past month.
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.
See More
Previous Close:
$1.80
Open:
$1.94
24h Volume:
294.44K
Relative Volume:
0.53
Market Cap:
$132.68M
Revenue:
-
Net Income/Loss:
$-64.20M
P/E Ratio:
-0.9074
EPS:
-2.15
Net Cash Flow:
$57,000
1W Performance:
+7.66%
1M Performance:
-13.39%
6M Performance:
+52.24%
1Y Performance:
-64.05%
1-Day Range:
$1.82
$1.9999
1-Week Range:
$1.54
$1.9999
52-Week Range:
$1.05
$5.47
Climb Bio Inc Stock (CLYM) Company Profile
Name
Climb Bio Inc
Sector
Industry
Phone
1-866-857-2596
Address
20 WILLIAM STREET, WELLESLEY HILLS
Compare CLYM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLYM
Climb Bio Inc
|
1.958 | 121.98M | 0 | -64.20M | 57,000 | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.42 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
471.68 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
552.74 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
809.14 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
331.34 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Climb Bio Inc Stock (CLYM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-15-25 | Initiated | Robert W. Baird | Outperform |
| Jun-06-25 | Initiated | Oppenheimer | Outperform |
| May-22-25 | Initiated | BTIG Research | Buy |
| Dec-02-24 | Initiated | Leerink Partners | Outperform |
Climb Bio Inc Stock (CLYM) Latest News
HC Wainwright Initiates Climb Bio at Buy With $9 Price Target - MarketScreener
Climb Bio Unveils Promising Preclinical Data for CLYM116 - MSN
Can technical indicators confirm Climb Bio Inc.’s reversalEarnings Recap Summary & Fast Entry High Yield Tips - newser.com
Climb Bio Inc. recovery potential after sell offJuly 2025 Fed Impact & Weekly High Return Opportunities - newser.com
Leading vs lagging indicators on Climb Bio Inc. performanceJuly 2025 Intraday Action & Safe Entry Point Alerts - newser.com
What technical models suggest about Climb Bio Inc.’s comebackJuly 2025 Outlook & Low Risk High Win Rate Picks - newser.com
Institutional scanner results for Climb Bio Inc.July 2025 Snapshot & Free Technical Pattern Based Buy Signals - newser.com
Visual analytics tools that track Climb Bio Inc. performanceQuarterly Profit Report & Community Verified Watchlist Alerts - newser.com
Relative strength of Climb Bio Inc. in sector analysisJuly 2025 Big Picture & AI Powered Buy/Sell Recommendations - newser.com
Climb Bio Inc. stock volume spike explainedMarket Movement Recap & AI Forecasted Entry and Exit Points - newser.com
Climb Bio (NASDAQ:CLYM) Given "Sell (D-)" Rating at Weiss Ratings - MarketBeat
Climb Bio Inc. stock prediction for this week2025 Sector Review & Safe Entry Zone Tips - newser.com
How to use Fibonacci retracement on Climb Bio Inc.Market Trend Report & Weekly Top Stock Performers List - newser.com
Can Climb Bio Inc. stock outperform in 2025 bull market2025 Major Catalysts & Growth Oriented Trading Recommendations - newser.com
Sector ETF performance correlation with Climb Bio Inc.Short Setup & Real-Time Market Trend Scan - newser.com
Climb Bio, Inc. (NASDAQ:CLYM) Sees Significant Drop in Short Interest - MarketBeat
Climb Bio Experiences Measurable Shift In Market Positioning - Kalkine Media
Climb Bio (NASDAQ:CLYM) Rating Increased to Hold at Wall Street Zen - Defense World
Climb Bio (NASDAQ:CLYM) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Analyzing Climb Bio Inc. with multi timeframe charts2025 Macro Impact & Consistent Income Trade Ideas - newser.com
Oppenheimer Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $10 - 富途牛牛
Climb Bio, Inc. (NASDAQ:CLYM) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Can Climb Bio Inc. recover in the next quarterMarket Risk Report & Reliable Trade Execution Plans - newser.com
Will Climb Bio Inc. stock deliver shareholder valueQuarterly Portfolio Summary & Growth-Oriented Investment Plans - newser.com
Climb Bio to be Added to the Nasdaq Biotechnology Index - FinancialContent
Climb Bio appoints Susan Altschuller as new CFO By Investing.com - Investing.com Nigeria
Climb Bio appoints Susan Altschuller as chief financial officer By Investing.com - Investing.com Nigeria
Former bluebird CEO picked to lead Inventiva - BioCentury
Climb Bio appoints Susan Altschuller as chief financial officer - Investing.com India
Climb Bio Appoints New CFO Susan Altschuller - TipRanks
Climb Bio Names Dr. Susan Altschuller CFO - MarketScreener
Leerink Partners Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $10 - 富途牛牛
Climb Bio appoints Susan Altschuller, Ph.D., MBA as chief financial officer - MarketScreener
Climb Bio Appoints Susan Altschuller, Ph.D., MBA as Chief Financial Officer - markets.businessinsider.com
Climb Bio appoints Susan Altschuller as new CFO - Investing.com
From $8.7B Cerevel Deal to Climb Bio: Biotech Veteran Susan Altschuller Takes CFO Role as Trials Advance - Stock Titan
Climb Bio stock price target raised to $8 from $7 at BTIG on CLYM116 potential - Investing.com Canada
Climb Bio reports NHP data with CLYM-116 - BioWorld MedTech
Climb Bio Inc Stock (CLYM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Climb Bio Inc Stock (CLYM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Pimblett Emily | SVP, Finance & CAO |
Jun 20 '25 |
Sale |
1.24 |
1,242 |
1,540 |
18,888 |
| Pimblett Emily | SVP, Finance & CAO |
Mar 20 '25 |
Sale |
1.31 |
1,199 |
1,571 |
15,130 |
| Pimblett Emily | CHIEF ACCOUNTING OFFICER |
Dec 19 '24 |
Sale |
2.02 |
1,235 |
2,495 |
11,329 |
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):